| Institution: | 1. Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
Institute for Applied Dermatopharmaceutics, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany;2. Department of Internal Medicine IV (Hematology and Oncology), Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany;3. Deparment of Gynecology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany;4. Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany |
| Abstract: | In accordance with article 20 of Regulation (EC) No 726/2004, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has re-evaluated the safety of Janus kinase inhibitors for the treatment of inflammatory diseases and formulated safety information deviating from the previous indications in the respective summary of product characteristics of the products concerned. These refer to the consideration of a possibly increased risk of venous thromboembolic or severe cardiovascular events, an increased infection rate and an increase in the prevalence of skin cancer across drugs and indications. Therefore, in patients with independent risk factors (age 65 years and older, smokers or former smokers, patients with oral contraception or hormone replacement therapy and other risk factors), it is recommended to use Janus kinase inhibitors therapeutically only if there are no suitable treatment alternatives. To facilitate a pragmatic and thorough detection of high-risk patients in everyday clinical practice, an interdisciplinary checklist was developed that is suitable as a working tool from the perspective of the dermatologist. |
